- Home
- LEO vs DMAC Comparison
LEO vs DMAC Comparison
Compare LEO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- DMAC
- Stock Information
- Founded
- LEO 1987
- DMAC 2000
- Country
- LEO United States
- DMAC United States
- Employees
- LEO N/A
- DMAC N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LEO Finance
- DMAC Health Care
- Exchange
- LEO Nasdaq
- DMAC Nasdaq
- Market Cap
- LEO 363.8M
- DMAC 178.0M
- IPO Year
- LEO N/A
- DMAC N/A
- Fundamental
- Price
- LEO $5.96
- DMAC $3.57
- Analyst Decision
- LEO
- DMAC Strong Buy
- Analyst Count
- LEO 0
- DMAC 2
- Target Price
- LEO N/A
- DMAC $8.00
- AVG Volume (30 Days)
- LEO 200.2K
- DMAC 307.0K
- Earning Date
- LEO 01-01-0001
- DMAC 08-06-2025
- Dividend Yield
- LEO 4.01%
- DMAC N/A
- EPS Growth
- LEO N/A
- DMAC N/A
- EPS
- LEO 0.04
- DMAC N/A
- Revenue
- LEO N/A
- DMAC N/A
- Revenue This Year
- LEO N/A
- DMAC N/A
- Revenue Next Year
- LEO N/A
- DMAC N/A
- P/E Ratio
- LEO $152.00
- DMAC N/A
- Revenue Growth
- LEO N/A
- DMAC N/A
- 52 Week Low
- LEO $4.98
- DMAC $2.72
- 52 Week High
- LEO $6.50
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- LEO 65.88
- DMAC 40.50
- Support Level
- LEO $5.77
- DMAC $3.70
- Resistance Level
- LEO $5.82
- DMAC $3.99
- Average True Range (ATR)
- LEO 0.04
- DMAC 0.31
- MACD
- LEO 0.02
- DMAC -0.01
- Stochastic Oscillator
- LEO 97.37
- DMAC 13.67
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.